Can a Biohybrid Patch Salvage Ventricular Function at a Late Time Point in the Post-Infarction Remodeling Process?
JACC Basic Transl Sci
; 6(5): 447-463, 2021 May.
Article
en En
| MEDLINE
| ID: mdl-34095634
A biohybrid patch without cellular components was implanted over large infarcted areas in severely dilated hearts. Nonpatched animals were assigned to control or losartan therapy. Patch-implanted animals responded with better morphological and functional echocardiographic endpoints, which were more evident in a subgroup of animals with very low pre-treatment ejection fraction (<35%). Patched animals also had smaller infarcts than both nonpatched groups. This simple approach could hold promise for clinical translation and be applied using minimally invasive procedures over the epicardium in a large set of patients to induce better ventricular remodeling, especially among those who are especially frail.
AT1R, angiotensin 1 receptor; ECM, extracellular matrix; EDA, end-diastolic area; EF, ejection fraction; ESA, end-systolic area; FS, fractional shortening; HF, heart failure; LV, left ventricle; LVEF, left ventricular ejection fraction; LVFW, left ventricular free wall; LVdd, left ventricular end-diastolic diameter; LVsd, left ventricular end-systolic diameter; M1, macrophage type 1; M2, macrophage type 2; MI, myocardial infarction; MT, Masson trichrome; PBS, phosphate-buffered saline; PECUU, poly(ester carbonate urethane) urea; PEUU, poly(ester urethane) urea; SMA, smooth muscle actin; biomaterial; cardiac patch; left ventricular remodeling; myocardial infarction
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
JACC Basic Transl Sci
Año:
2021
Tipo del documento:
Article
País de afiliación:
Estados Unidos